J7643 HCPCS Level II code: Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

J7643 is the HCPCS code for “Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J7643

Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

Short description: Glycopyrrolate comp unit

HCPCS · United States

Notes for J7643

As CMS prints them, with any note J7643 takes from the headings above it.

Note

  • CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).

Medicare details

The indicators CMS publishes with J7643 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
Drugs
Type of service
Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category
Drugs Administered through DME
Added
Jan 1, 2000

Where J7643 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J7643Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J7643 mean?

J7643 is the HCPCS code for “Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J7643?

CMS lists J7643’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.

J7637Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7638Dexamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7639Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7640Formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 microgramsJ7641Flunisolide, inhalation solution, compounded product, administered through dme, unit dose, per milligramJ7642Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7644Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7645Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7647Isoetharine hcl, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7648Isoetharine hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per milligramJ7649Isoetharine hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligramJ7650Isoetharine hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligram